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Purpose: VerifyNow antiplatelet assays were performed before and after stenting for various cerebral artery
stenoses to determine the effect of the procedure itself to the function of dual antiplatelets given. 
Materials and Methods: A total of 30 consecutive patients underwent cerebral arterial stenting proce-
dure were enrolled. The antiplatelet pretreatment regimen was aspirin (100 mg daily) and clopido-
grel (300 mg of loading dose followed by 75mg daily). VerifyNow antiplatelet assay performed
before and right after stenting. The two test results were compared in terms of aspirin-reaction
unit (ARU), P2Y12 reaction units (PRU), baseline (BASE), and percentage inhibition. We evaluated
occurrence of any intra-procedural in-stent thrombosis or immediate thromboembolic complica-
tion, and ischemic events in 1-month follow-up.
Results: The median Pre-ARU was 418 (range, 350-586). For clopidogrel the medians of the pre-BASE,
PRU, and percent inhibition were 338 (279-454), 256 (56-325), and 27% (0-57%). The medians of
the post-ARU, BASE, PRU, and percent inhibition after stenting were 469 (range, 389-573), 378
(288-453), 274 (81-370), and 26% (0-79%). There was a significant increase of ARU (p=0.045),
BASE (p=0.026), and PRU (p=0.018) before and after stenting. One immediate thromboembolic
event was observed in poor-response group after stenting. There was no in-stent thrombosis and
ischemic event in 1-month follow-up.
Conclusion: We observed a significant increase of platelet reactivity to dual antiplatelet therapy right
after stenting procedure for various cerebral arterial stenoses. 
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http://dx.doi.org/10.5469/neuroint.2012.7.1.23Dual-antiplatelet treatment has become a standard pre-
treatment medication for cerebrovascular stenting
procedures such as carotid/vertebral artery stenting or
intracranial artery stenting. Since the retraction of
ticlopidine, oral administration of aspirin and clopidogrel
is the standard regimen in most of the cases [1-3].
However, recently there has been growing concern about
poor biochemical resistance to the antiplatelet therapy
especially to clopidogrel in our neurovascular arena and
among our cardiology colleagues as well [4-7].
Owing to the recent advent of a point-of-care assay
for the antiplatelet monitoring, such as VerifyNow
Assay (Accumetrics, San Diego, CA, U.S.A.), it has
become quite easy and convenient to monitor
antiplatelet function of both aspirin and clopidogrel [6,
8, 9]. According to our recent experience, poor
response rate to clopidogrel was quite high in our
neurovascular patients group as well [6]. However, in
the generalization and interpretation of the test result,
e.g., percent inhibition (% inhibition) and P2Y12
reaction unit (PRU), we found there was no solid cut-
off values of poor response. Each paper reports its own
definition and result [10-14]. 
There have been several possible suggestions on the
possible etiology of poor response to clopidogrel [5,
15]. In addition to the individual variability of clopido-
grel response, we hypothesized that the measurement
result could be varied by the timing of measurement.
Although we are focusing on the pre-stenting value of
the test in most of the cases, some are focusing on the
post-procedural test result for the prediction of long-
term effect of the clopidogrel treatment [16]. 
In this study we focused on the possible influence of
stenting procedure itself to the test result. We hypothe-
sized that the test result could be increased by intra-
arterial procedure itself since the intravascular manipu-
lation using various intravascular devices and the
remained stent mesh in the arterial lumen might
increase platelet reactivity.
MATERIALS AND METHODS
Patients
After obtaining an approval of our institutional
review board, we prospectively enrolled patients who
underwent elective supraaortic and/or cerebrovascular
stenting procedures due to atherosclerotic stenosis of
the internal carotid artery (ICA), subclavian artery,
vertebral artery, or intracranial arteries from October
2008 to September 2009. Exclusion criteria were
insufficient antiplatelet pre-treatment before the
procedure. There was no control group in this study.
Our definition of sufficient antiplatelet pretreatment
was more than 5 days of dual antiplatelet medication
with daily doses of 100 mg of aspirin and 75 mg of
clopidogrel following loading doses of 300-500 mg of
aspirin and 300 mg of clopidogrel.
Procedure and antiplatelet function assay
We double checked whether the patient had his/her
morning dose of antiplatelets before the procedure.
Immediately after insertion of the femoral artery
sheath, 9 ml of arterial blood was drawn to measure
baseline activated clotting time (ACT) and pre-
procedural VerifyNow Aspirin and P2Y12 Assays
(Accumetrics, San Diego, CA. U.S.A.), which were
pre-procedural aspirin reaction unit (Pre-ARU) for
aspirin, and pre-procedural base value (Pre-BASE),
pre-procedural P2Y12 reaction unit (Pre-PRU), and
pre-procedural percent inhibition (Pre-%inhibition) for
clopidogrel. Technical details of the assay were already
described before [6].
Stenting procedure was performed after systemic
heparinization and the target ACT value was 250-300
sec. We waited 15 to 20 minutes after completion of the
stenting to check any occurrence of acute in-stent
thrombosis or distal thromboembolism. Right before
the removal of the femoral sheath, another 9 ml of
arterial blood was drawn to measure post-procedural
ACT, Post-ARU, Post-BASE, Post-PRU, and Post-
%inhibition. We did not give any additive dosage of
antiplatelet according to the test result unless there was
any thrombotic complication during or after the
procedure since we did not have any solid evidence of
proper platelet function inhibition for the neurovascular
stenting procedure yet.
Post-procedural care and Analysis
After the procedure the patient was sent to neurologi-
cal intensive care unit. We carefully monitored the
patient for the occurrence of any neurological change.
If the patient was stable for 24 hours we transferred the
patient to general ward. Any occurrence of clinical
event was noticed for one month afterwards.
Statistical analysis was performed using SPSS
(SPSS, Inc., Chicago, IL, U.S.A.). We summarized the
two test results, pre- and post-procedural values of the
antiplatelet function assay by presenting medians and
their ranges or quartile ranges of ARU, PRU, BASE,
and % inhibition. We compared the pre- and post-
procedural values of the assay with use of Wilcoxon
signed-rank test.
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A total of 30 patients were enrolled in this study.
There were 23 men and 7 women with their mean age
of 62.6 years. The target lesion location was the
proximal ICA in 12, distal ICA in 2, middle cerebral
artery in 6, subclavian artery in 2, and vertebrobasilar
system in 8. 
The median Pre-ARU was 418 (range, 350-586).
For clopidogrel the medians of the pre-BASE, PRU,
and % inhibition were 338 (range, 279-454), 256
(range, 56-325), and 27% (range, 0-57%). After
stenting, the medians of the post-ARU, BASE, PRU,
and % inhibition were 469 (range, 389-573), 378
(range, 288-453), 274 (range, 81-370), and 26%
(range 0-79%). There were significant changes of
ARU (p = 0.045), BASE (p = 0.026), and PRU (p =
0.018) before and after stenting (Fig. 1). Since the
BASEs and PRUs increased at the same time, there
was no significant difference in percent inhibitions. 
There was no acute in-stent thrombosis or distal
thromboembolism during the procedure. However,
there was a case of delayed symptomatic patient who
showed mild facial weakness and dizziness about five
hours after the completion of proximal basilar artery
stent placement. Diffusion-weighted image obtained
thereafter showed acute infarction at lower medulla and
cerebellum suggesting stent-associated ischemic
lesions. His pre- and post- ARUs, BASEs, PRUs, and
% inhibitions were 418 and 560, 413 and 432, 299 and
270, and 27% and 37%. His symptom gradually
improved overtime without residual deficit. There was
no further ischemic event on 1-month follow-up. There
was no further clinical event during the one-month
follow-up period.
DISCUSSION
The importance of dual-antiplatelet pretreatment with
use of aspirin and clopidogrel cannot be over-
emphasized in our neurovascular stenting procedures.
Even with strict coverage more than 3 days, we
occasionally experience acute or subacute thrombo-
embolic phenomena during or after the procedure. Poor
biochemical response to both aspirin and/or clopidogrel
has been postulated as the possible cause of poor
antiplatelet response [4]. With advent of a convenient
point-of-care testing device, we can adjust our
antiplatelet regimen on individual basis by administrat-
ing double loading doses and/or increased maintenance
doses [6, 7, 17].
With accumulation of our experience, we became
realized that poor response to clopidogrel is much more
frequent than poor response to aspirin and PRU is more
ideal than % inhibition in terms of poor response to
clopidogrel [6, 7, 17]. The question is what are the cut-
off values of the test results? To answer the question,
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Fig. 1. Individual changes of ARU (A) and PRU (B) values before and after the stenting procedures. several studies have been undergone by applying the
cut-off values calculated with receiver-operating-curve
analysis or 4th quartile range as the high risk group [11,
13, 14]. Although the cut-off values of PRU are around
230-260, there is quite large variability of the values
from report to report. 
We believe that each institution should have its own
cut-off value for this. In setting up individual internal
reference values, consistency in clinical factors should
be considered. One of possible influencing factors
could be the timing of blood sampling as we observed
in this study. The study idea was based on the idea that
intravascular manipulation of various interventional
devices such as catheters, guidewires, balloon
angioplasty catheters, and/or stents and repeat use of
iodinated contrast media may influence on the reactiv-
ity of partially inhibited platelets due to dual-
antiplatelet pretreatment. In the interpretation of a
certain test result, we can overestimate antiplatelet
reactivity if the blood sample was taken after the
procedure. 
There are several limitations of this study. The
number of patient was small. However, we did not feel
a strong need of larger patient size since we could
observe statistically significant increase of platelet
reactivity after procedure with our limited patient
cohort. Another limitation was we could not correlate
the change with occurrence of any clinical event.
However, since there was no case of acute in-stent
thrombosis in our case and there was only one patient
who was symptomatic after the procedure, it was
impossible to draw any conclusion on the clinical
significance of our observation. Large patient size
could answer this question.
With a point-of-care assay, we observed a significant
increase of platelet reactivity to dual antiplatelet
therapy after stenting procedure for cerebral arterial
stenosis. Consistency in measurement timing should be
considered in setting up an institutional internal
reference values of the assay.
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